Higher Sensitivity of the recomLine Borrelia IgG Immunoblot Kit than of the Standard Lyme IgG Immunoblot Kit According to CDC Testing Criteria

TitleHigher Sensitivity of the recomLine Borrelia IgG Immunoblot Kit than of the Standard Lyme IgG Immunoblot Kit According to CDC Testing Criteria
Publication TypeJournal Article
Year of Publication2018
AuthorsKadkhoda K, Gretchen A
JournalJ Clin Microbiol.
Volume56
Issue8
Date Published07/2018
Abstract

Lyme disease (LD), caused by Borrelia burgdorferi sensu lato, is the most common tick-borne disease in the United States and Canada. Left untreated, LD may progress through three stages: an early localized stage (hallmarked by an erythema migrans [EM] rash), the early disseminated stage, and the late stage (1). Serodiagnosis offers suboptimal sensitivity during the first stage. The recommended two-tiered testing algorithm by the U.S. Centers for Disease Control and Prevention (CDC) requires screening by an enzyme-linked immunosorbent assay (ELISA), and if the results are positive/equivocal, at least 5 out of 10 diagnostic bands (p18, OspC, p28, p30, p39, p41, p45, p58, p66, and p93) must be present on an IgG immunoblot for a confirmed positive result (2).

URLhttps://jcm.asm.org/content/56/8/e00527-18.long